-
Meteor lights up night sky over parts of US and Canada - 7 mins ago
-
Ysabel Jurado vanquished Kevin de León. Will winning change her? - 8 mins ago
-
Seahawks Starting Center Connor Williams Shockingly Retires from the NFL Mid-season - 9 mins ago
-
Rachel Zegler Apologizes for Trump Rant, But Did She Really Go Too Far? - 10 mins ago
-
Underrated NWSL playoff performers: Who can make the difference as Spirit host Gotham, Pride face Current - 13 mins ago
-
Walworth market stabbing victim was warm and kind, family says - 16 mins ago
-
Robert Roberson’s execution can resume, Texas Supreme Court says - 23 mins ago
-
Hugh Grant, 64, Jokes Having 5 Children Is ‘Unbearable’ at Times - 24 mins ago
-
La Ronge, Sask. doctors diagnose 27 cases of scurvy, highlighting food insecurity - 26 mins ago
-
Everything you should know about travelling over Christmas 2024, from train alternatives to airport tips - 27 mins ago
ALS drug will be pulled from Canada, U.S. markets after failed trial – National
Amylyx Pharmaceuticals will withdraw its amyotrophic lateral sclerosis (ALS) drug – its only product in the market – from the U.S. and Canada after the treatment failed in a key late-stage trial.
The drugmaker on Thursday also announced a 70 per cent reduction in its workforce. It had 384 full-time employees at the end of 2023.
The ALS drug, branded Relyvrio, was approved in 2022 after lobbying by patient groups who pointed to limited options to treat the potentially fatal disease.
ALS causes progressive paralysis and death, and affects roughly 60,000 people in the U.S. and Europe.
Approval followed a rare turnaround by the U.S. Food and Drug Administration’s advisers. They backed the drug months after rejecting it for a lack of “substantially persuasive” data.
The approval was based on mid-stage trial data in 137 patients that showed the treatment slowed disease progression and extended life expectancy.
However, a larger late-stage study failed to confirm the reported benefit of slowing disease progression, with no significant difference in patients treated with Relyvrio and placebo.
The drug, which has a list price of USD$158,000 per year in the U.S., generated sales of about $381 million in 2023.
The latest health and medical news
emailed to you every Sunday.
Amylyx expects to incur charges of about $19 million as part of its restructuring, expected to be completed by the end of the third quarter.
Shares closed about 83 per cent lower and more than $1 billion was wiped out from its market value on March 8 after the company disclosed it was considering withdrawing the treatment.
The company will advance trials of its lead experimental drug AMX0035 in inherited condition Wolfram syndrome and neurological disorder progressive supranuclear palsy. It will also focus on AMX0114 in ALS.
Source link